首页> 外文期刊>Clinical Genetics: An International Journal of Genetics in Medicine >Homozygous TMEM127 TMEM127 mutations in 2 patients with bilateral pheochromocytomas
【24h】

Homozygous TMEM127 TMEM127 mutations in 2 patients with bilateral pheochromocytomas

机译:2例双侧嗜铬细胞瘤患者的纯合TMEM127 TMEM127突变

获取原文
获取原文并翻译 | 示例
       

摘要

Pheochromocytoma (PCC) and paraganglioma (PGL) are rare neuroendocrine tumors that are hereditary in up to 50% of patients. The gene encoding transmembrane‐protein‐127 ( TMEM127 ) is one of the PCC/PGL‐susceptibility genes with an autosomal dominant inheritance pattern. Here, we report 2 patients with bilateral PCC who both harbored a homozygous TMEM127 ‐mutation. In a 31‐year‐old mentally retarded patient, the homozygous c.410‐2A G mutation was discovered during an update of DNA analysis. A 26‐year‐old mentally retarded patient was found to have a homozygous c.3G A mutation. The parents of both patients were consanguineous. We reviewed previously reported clinical features of TMEM127 mutation carriers and compared our findings with case descriptions of homozygous mutations in other PGL/PCC‐susceptibility genes. Homozygosity for an autosomal dominant inherited disorder is an extremely rare phenomenon and has, to our knowledge, not been reported before for the gene encoding TMEM127 . In the present cases, the clinical picture does not seem to be very different from heterozygous TMEM127 mutation carriers, except for a relatively large tumor size and more pronounced plasma metanephrine concentration. It is unclear whether the mental retardation is causally related to homozygosity of the TMEM127 mutations. Updating genetic screening in patients in whom PCC/PGL has been diagnosed in the past should be considered as it might provide clinically relevant information.
机译:Pheochromytoma(PCC)和Paraganglioma(PG1)是罕见的神经内分泌肿瘤,遗传患者患者的遗传性高达50%。编码跨膜蛋白-127(TMEM127)的基因是具有常染色体显性遗传模式的PCC / PGL-易感基因之一。在这里,我们报告2例双侧PCC患者,谁患有纯合的TMEM127 - 蒙古。在31岁的智力迟钝的患者中,纯合C.410-2A&在更新DNA分析期间发现了G突变。发现了一个26岁的智力迟钝的患者有纯合C.3g&一个突变。两名患者的父母都是近端的。我们审查了先前报告了TMEM127突变载体的临床特征,并将我们的发现与其他PGL / PCC易感基因中的纯合突变的病例进行了比较。对于常染色体显性遗传障碍的纯合子是一种极其罕见的现象,并且在编码TMEM127之前没有报道我们的知识。在本病例中,除了相对大的肿瘤大小和更明显的血浆Metanephrine浓度之外,临床图像似乎与杂合子TMEM127突变载体似乎没有非常不同。目前尚不清楚施工延迟是否因TMEM127突变的纯合子而导致有因而相关。更新在过去诊断的患者中的遗传筛选应考虑在可能提供临床相关信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号